Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Accounts Payables (2016 - 2020)

Historic Accounts Payables for Larimar Therapeutics (LRMR) over the last 8 years, with Q3 2020 value amounting to $1.3 million.

  • Larimar Therapeutics' Accounts Payables fell 6176.56% to $1.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was $1.3 million, marking a year-over-year decrease of 6176.56%. This contributed to the annual value of $3.5 million for FY2019, which is 142.06% down from last year.
  • Per Larimar Therapeutics' latest filing, its Accounts Payables stood at $1.3 million for Q3 2020, which was down 6176.56% from $2.3 million recorded in Q2 2020.
  • Larimar Therapeutics' 5-year Accounts Payables high stood at $4.4 million for Q2 2017, and its period low was $322000.0 during Q1 2020.
  • Over the past 5 years, Larimar Therapeutics' median Accounts Payables value was $3.0 million (recorded in 2018), while the average stood at $2.8 million.
  • In the last 5 years, Larimar Therapeutics' Accounts Payables skyrocketed by 9874.35% in 2018 and then plummeted by 8979.72% in 2020.
  • Quarter analysis of 5 years shows Larimar Therapeutics' Accounts Payables stood at $2.6 million in 2016, then grew by 17.42% to $3.0 million in 2017, then rose by 18.87% to $3.6 million in 2018, then decreased by 1.42% to $3.5 million in 2019, then crashed by 64.14% to $1.3 million in 2020.
  • Its last three reported values are $1.3 million in Q3 2020, $2.3 million for Q2 2020, and $322000.0 during Q1 2020.